Looking for research-grade compounds?
CJC-1295 peptide research is the study of a synthetic growth hormone-releasing hormone (GHRH) analog designed to last far longer than the natural hormone. Native GHRH is cleared in minutes, making it a poor tool for sustained signaling questions. CJC-1295 peptide research solved that in two ways — an albumin-binding long-acting form and a short-acting form — and confusion between those two forms is the biggest source of error in this literature. This guide separates them and reviews the human data and regulatory status.
CJC-1295 was developed by ConjuChem Biotechnologies, building on work by Jetté and colleagues in Endocrinology (2005) on GHRH(1-29)-albumin bioconjugates. The starting point is the first 29 amino acids of human GHRH — the active fragment, GRF(1-29) — with substitutions, including D-alanine at position 2, that resist cleavage by dipeptidyl peptidase-IV (DPP-IV).
From that shared backbone, two distinct research materials emerge:
That distinction is not pedantry. Almost every headline number in CJC-1295 peptide research — the multi-day half-life, the week-long IGF-1 elevation — comes from studies of the DAC form. Applying those numbers to a no-DAC vial is a category error, and any supplier or article that does so without qualification should be read with skepticism.
| Feature | CJC-1295 with DAC | CJC-1295 without DAC (Modified GRF 1-29) |
|---|---|---|
| Core structure | Modified GHRH(1-29) analog plus albumin-binding DAC linker | Modified GHRH(1-29) analog only; four reported substitutions for stability |
| Defining mechanism | Covalent binding to serum albumin after administration in study models | No albumin binding; cleared as a conventional small peptide |
| Reported half-life | 5.8–8.1 days in healthy adults (Teichman et al., JCEM, 2006) | Roughly 30 minutes is commonly reported in secondary sources; not established in controlled human studies of this exact form |
| GH / IGF-1 pattern in studies | Sustained elevation over days, with pulsatility preserved on an elevated baseline | Short, pulse-like GHRH-receptor activation in preclinical and mechanistic work |
| Human evidence | Two randomized, placebo-controlled Phase 1 studies in healthy adults | Largely uncharacterized in controlled human trials as a standalone molecule |
| FDA status | Not FDA-approved for any indication | Not FDA-approved for any indication |
For identity purposes, the two forms must also separate cleanly on a certificate of analysis. Because their masses differ, mass spectrometry is the identity check that can tell a DAC conjugate, a no-DAC peptide, and a mislabeled vial apart — a point we return to in the lab considerations below.
CJC-1295 acts at the GHRH receptor, a G protein-coupled receptor expressed on somatotroph cells in the anterior pituitary. In cellular models, receptor activation raises intracellular cyclic AMP through adenylate cyclase, activating protein kinase A signaling that promotes both the synthesis and the release of growth hormone (GH). GH then drives production of insulin-like growth factor 1 (IGF-1), principally in the liver, which is why CJC-1295 peptide research measures both hormones: GH as the direct pituitary output, and IGF-1 as the more stable downstream marker that integrates GH exposure over time.
Three features of this axis matter for interpreting the data honestly:
GH is released in pulses, largest during sleep, with low troughs between. Tissues read that pattern, not just the average — which is why a long-acting analog raises a genuine research question rather than simply being a stronger short-acting one.
A GHRH analog works upstream, through the pituitary’s own machinery. Somatostatin can still blunt release, and IGF-1 feedback still operates — pituitary-level regulation is preserved, not bypassed.
In a companion study, Ionescu and Frohman (Journal of Clinical Endocrinology & Metabolism, 2006) examined GH secretion patterns during CJC-1295 exposure and found that pulsatile GH secretion persisted. What changed was the trough: basal GH between pulses was elevated, so mean GH rose even though the pulse structure remained. The accurate summary is pulses on an elevated baseline sustained for days — not a flat plateau, and not a normal pattern either.
The core human evidence for CJC-1295 is real but narrow, and it is worth stating precisely what was measured and what was not.
The most-cited study in CJC-1295 peptide research is Teichman and colleagues in the Journal of Clinical Endocrinology & Metabolism (2006), reporting two randomized, placebo-controlled, double-blind ascending-dose trials in healthy adults aged 21 to 61. After a single administration of CJC-1295 with DAC, mean plasma GH rose dose-dependently by roughly 2- to 10-fold for six days or more, and mean IGF-1 rose by roughly 1.5- to 3-fold for nine to eleven days. The estimated half-life was 5.8 to 8.1 days, and after repeated administration IGF-1 remained above baseline for up to 28 days in that study. No serious adverse reactions were reported in those short trials.
Those are pharmacodynamic findings — proof that the molecule engages its target axis in humans and moves two biomarkers in the expected direction, for an unusually long time. They are not outcome findings. The trials were not designed to test, and did not establish, any effect on body composition, strength, recovery, sleep, or aging in healthy adults.
Alba and colleagues (2006) reported that the long-acting analog normalized growth measures in mice genetically lacking GHRH — a clean mechanistic test of whether a stabilized analog can substitute for the missing signal. Knockout-rescue results in mice do not translate directly to humans with an intact axis.
CJC-1295 advanced into Phase 2 investigation, including in HIV-associated lipodystrophy, but development was discontinued and no approved product followed. Secondary accounts describe a participant death during that trial that was investigated at the time — part of why the absence of long-term human safety data is a substantive gap, not a formality. The longest published Phase 1 exposure was measured in weeks.
| Compound | Class | Regulatory / research note |
|---|---|---|
| CJC-1295 (with or without DAC) | GHRH analog | Investigational only; no FDA approval; human data limited to short biomarker studies of the DAC form |
| Tesamorelin | GHRH analog | FDA-approved for one specific indication — reducing excess abdominal fat in adults with HIV-associated lipodystrophy; its label states it is not indicated for weight-loss management. See our tesamorelin research profile in the research peptide catalog |
| Sermorelin | GHRH(1-29) analog | The unmodified-duration predecessor concept: a short-acting GRF(1-29) compound formerly marketed as an approved product, now mainly encountered as a historical comparator |
| Ipamorelin | Ghrelin / GHS-R1a secretagogue | Different receptor entirely — it does not act at the GHRH receptor. It is often discussed alongside CJC-1295 because the two pathways converge on pituitary GH release, but no published human randomized trial has tested the combination |
The tesamorelin comparison is instructive: same receptor family, two different regulatory outcomes — one molecule completed approval for a narrow indication, the other did not complete development.
FDA approval: CJC-1295 is not approved by the U.S. Food and Drug Administration for any indication, in either form, and no approved drug product contains it.
Compounding history: FDA placed CJC-1295 in Category 2 of its interim 503A bulks list in 2023 — for substances presenting significant safety concerns — citing immunogenicity risk, complexities in characterizing peptide-related impurities, serious adverse events including increased heart rate and a systemic vasodilatory reaction, and limited clinical data. The nomination was later withdrawn and it was removed from Category 2 — a procedural change, not an approval or a finding of safety. On December 4, 2024, FDA’s Pharmacy Compounding Advisory Committee voted against recommending CJC-1295 for the 503A bulks list, 0 to 13 on most forms. Check FDA’s current listings directly; this status has moved several times.
Anti-doping: CJC-1295 is named on the World Anti-Doping Agency Prohibited List under S2, peptide hormones and releasing factors, as a GHRH analog. Substances in that class are prohibited at all times, in and out of competition, with no distinction between the DAC and no-DAC forms.
Research-use-only framing: None of the above is changed by a label. As our overview of what research use only actually means explains, RUO describes the intended laboratory purpose of a material — it does not create an approved human use.
No. Neither the DAC nor the no-DAC form is FDA-approved for any indication, and neither is an approved drug product in the United States. Tesamorelin, a different GHRH analog, is approved for a specific HIV-associated lipodystrophy indication — that approval does not extend to CJC-1295.
The DAC form carries an albumin-binding linker that produced a reported 5.8- to 8.1-day half-life in Phase 1 human studies. The no-DAC form, Modified GRF(1-29), lacks that linker, is a smaller and chemically distinct molecule, and lacks comparable controlled human pharmacokinetic data. Their GH patterns, evidence bases, and COA identity values are different.
No. The controlled human studies measured GH and IGF-1 — biomarkers of target engagement — over days to weeks in healthy adults. They were not outcome trials, and no controlled human evidence establishes those broader effects.
Because the mechanisms are complementary on paper: CJC-1295 acts at the GHRH receptor, while ipamorelin acts at the ghrelin receptor (GHS-R1a), and both converge on pituitary GH release. That is a mechanistic rationale, not clinical evidence — no published human randomized trial of the combination was identified in the current literature.
CJC-1295 peptide research contains one genuinely strong finding — a long-acting GHRH analog that raised GH and IGF-1 for days after a single administration in placebo-controlled human studies — surrounded by much weaker material that borrows its credibility. Keep the DAC and no-DAC molecules separate, keep biomarker results separate from outcomes, and keep the regulatory record in view: investigational, unapproved, and prohibited in tested sport. Judged that way, CJC-1295 remains a useful research tool for studying sustained GHRH-receptor signaling, which is exactly the purpose it is supplied for. See the CJC-1295 No DAC + Ipamorelin research product for the no-DAC form’s batch documentation.
All Apex Bio Industries compounds are supplied strictly for laboratory research use only. This article is educational content about published research and regulatory status and does not constitute medical, safety, or usage advice. Research peptides are not for human or veterinary use, and nothing on this site should be interpreted as instructions for administration, dosing, or personal use.
Researchers studying GHRH-axis compounds can browse the full research peptides collection for related materials.
Selank peptide research starts with an unusual origin story. Most research peptides begin as fragments of a hormone or growth
Retatrutide Peptide Research: The Triple Agonist, TRIUMPH Trials and FDA Status Retatrutide peptide research is where incretin science stopped adding
Sermorelin Peptide Research: GHRH(1-29), GH Pulses and FDA History Sermorelin peptide research occupies an unusual place in the peptide literature:
